Survival, ventricular arrhythmia, and implantable cardioverter‐defibrillator usefulness in toxic cardiomyopathy due to substance abuse
Pacing and Clinical Electrophysiology · 2023
DOI: 10.1111/pace.14720 ↗At a glance
Journal article in Pacing and Clinical Electrophysiology, 2023. Written by Nicolas Dognin and 17 co-authors. Institution: Département multidisciplinaire de cardiologie, Institut Universitaire de Cardiologie et de Pneumologie de Québec-Université Laval, Quebec City, Canad…. Major MEDLINE topics: Defibrillators, Implantable, Cardiomyopathies, Cardiomyopathy, Dilated, Substance-Related Disorders. Cited 4 times so far (Crossref); 57 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Background
Toxic dilated cardiomyopathy (T‐DCM) due to substance abuse is now recognized as a potential cause of severe left ventricular dysfunction. The burden of ventricular arrhythmias (VA) and the role of a prophylactic implantable cardioverter‐defibrillator (ICD) are not well documented in this population. We aim to assess the usefulness of ICD implantation in a T‐DCM cohort.
Methods
Patients younger than 65 years with a left ventricular ejection fraction (LVEF) < 35% followed at a tertiary center heart failure (HF) clinic between January 2003 and August 2019 were screened for inclusion. The diagnosis of T‐DCM was confirmed after excluding other etiologies, and substance abuse was established according to the DSM‐5 criteria. The composite primary endpoints were arrhythmic syncope, sudden cardiac death (SCD), or death of unknown cause. The secondary endpoints were the occurrence of sustained VA and/or appropriate therapies in ICD carriers.
Results
Thirty‐eight patients were identified, and an ICD was implanted in 19 (50%) of these patients, only one for secondary prevention. The primary outcome was similar between the two groups (ICD vs. non‐ICD; p = 1.00). After a mean follow‐up of 33 ± 36 months, only two VA episodes were reported in the ICD group. Three patients received inappropriate ICD therapies. One ICD implantation was complicated with cardiac tamponade. Twenty‐three patients (61%) had an LVEF ≥35% at 12 months.
Conclusion
VA are infrequent in the T‐DCM population. The prophylactic ICD benefit was not observed in our cohort. The ideal timing for potential prophylactic ICD implantation in this population needs further studies.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Département multidisciplinaire de cardiologie, Institut Universitaire de Cardiologie et de Pneumologie de Québec-Université Laval, Quebec City, Canada.
ORCID profiles: Guillaume Domain, David Belzile
Cite
APA
Dognin, N., Rimac, G., Domain, G., Cinq-Mars, A., Massot, M., Turgeon, P. Y., Dubois-Sénéchal, S. M., Bourgault, C., Morin, J., Bernier, M., Beaudoin, J., Laflamme, M., Charbonneau, E., Strubé, C., Voisine, P., Philippon, F., Belzile, D., & Sénéchal, M. (2023). Survival, ventricular arrhythmia, and implantable cardioverter‐defibrillator usefulness in toxic cardiomyopathy due to substance abuse. Pacing and Clinical Electrophysiology. https://doi.org/10.1111/pace.14720
Vancouver
Dognin N, Rimac G, Domain G, Cinq-Mars A, Massot M, Turgeon PY, et al. Survival, ventricular arrhythmia, and implantable cardioverter‐defibrillator usefulness in toxic cardiomyopathy due to substance abuse. Pacing and Clinical Electrophysiology. 2023. doi:10.1111/pace.14720
BibTeX
@article{Dognin2023,
author = {Dognin, Nicolas and Rimac, Goran and Domain, Guillaume and Cinq-Mars, Alexandre and Massot, Montse and Turgeon, Pierre Yves and Dubois-Sénéchal, Sacha-Michelle and Bourgault, Christine and Morin, Joëlle and Bernier, Mathieu and Beaudoin, Jonathan and Laflamme, Maxime and Charbonneau, Eric and Strubé, Camille and Voisine, Pierre and Philippon, François and Belzile, David and Sénéchal, Mario},
title = {Survival, ventricular arrhythmia, and implantable cardioverter‐defibrillator usefulness in toxic cardiomyopathy due to substance abuse},
journal = {Pacing and Clinical Electrophysiology},
year = {2023},
doi = {10.1111/pace.14720}
}
EUVIMED